Aug 18, 2017

GNS Co-Founder Iya Khalil Interviewed in The Pink Sheet

PinkSheetAt the 2017 BIO International Convention, GNS Co-Founder and Chief Commercial Officer Iya Khalil sat down with Laura Helbling, the Director of Research at Prevision Policy and a Senior Writer at Pink Sheet to discuss machine learning in drug development.
The conversation focused on how GNS’ causal machine learning and simulation platform applied to massive data sets can lead to breakthroughs in understanding clinical outcomes. The platform, REFS, excels at discovering new biology through reverse engineering the cause and effect relationships between variables, pulling novel insights directly from observational data. Iya also addressed how healthcare organizations can make better use of real world evidence to drive value-based contracting and better quality care for patients.
Read the full article here.